NeoGenomics, Inc. Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain
NeoGenomics, Inc. (NEO) reported Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-20.
Discontinued › Income Statement › Other Income
us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain · last filed 2024-02-20
- NeoGenomics, Inc. business combination, step acquisition, equity interest in acquiree, remeasurement gain for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- NeoGenomics, Inc. business combination, step acquisition, equity interest in acquiree, remeasurement gain for the quarter ending 2021-09-30 was $17.75M.
- NeoGenomics, Inc. business combination, step acquisition, equity interest in acquiree, remeasurement gain for the quarter ending 2020-12-31 was $3.96M.
- NeoGenomics, Inc. business combination, step acquisition, equity interest in acquiree, remeasurement gain for the quarter ending 2020-09-30 was $0.00.
- NeoGenomics, Inc. business combination, step acquisition, equity interest in acquiree, remeasurement gain for fiscal 2023 was $0.00.
- NeoGenomics, Inc. business combination, step acquisition, equity interest in acquiree, remeasurement gain for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- NeoGenomics, Inc. business combination, step acquisition, equity interest in acquiree, remeasurement gain for fiscal 2021 was $109.26M, a 2662.58% increase from fiscal 2020.
- NeoGenomics, Inc. business combination, step acquisition, equity interest in acquiree, remeasurement gain for fiscal 2020 was $3.96M.
| Period end | Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain 3 month | Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain 6 month | Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain 9 month | Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-20 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-20 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $17.75M derived: sum of 2 quarters · filed 2024-02-20 | $109.26M 10-K · filed 2024-02-20 | |
| 2021-09-30 | $17.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $109.26M 10-Q · filed 2021-11-04 | ||
| 2021-06-30 | $91.51M 10-Q · filed 2021-08-09 | |||
| 2020-12-31 | $3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | $3.96M derived: sum of 2 quarters · filed 2023-02-24 | $3.96M 10-K · filed 2023-02-24 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| 20/20 Biolabs, Inc. (AIDX) | United States | $0.005B |